Perspectives
Nature Reviews Cancer 8, 714-724 (September 2008) | doi:10.1038/nrc2401
Article series: RB and E2F
Opinion: Tailoring to RB: tumour suppressor status and therapeutic response
Erik S. Knudsen1 & Karen E. Knudsen1 About the authors
Abstract
The retinoblastoma tumour suppressor (RB) is a crucial regulator of cell-cycle progression that is invoked in response to a myriad of anti-mitogenic signals. It has been hypothesized that perturbations of the RB pathway confer a synonymous proliferative advantage to tumour cells; however, recent findings demonstrate context-specific outcomes associated with such lesions. Particularly, loss of RB function is associated with differential response to wide-ranging therapeutic agents. Thus, the status of this tumour suppressor may be particularly informative in directing treatment regimens.
Author affiliations
-
Erik S. Knudsen and Karen E. Knudsen are at the Department of Cancer Biology, and Karen E. Knudsen is at the Department of Urology, Kimmel Cancer Center, Bluemle Life Science Building-Room 1002, 233 South 10th Street, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.
Email: eknudsen@kimmelcancercenter.org
Email: kknudsen@kimmelcancercenter.org
Published online 7 August 2008
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
A mismatched role for Bcl-2Nature Cell Biology News and Views (01 Feb 2005)
Transcriptional repression The cancer-chromatin connectionNature News and Views (05 Feb 1998)
RESEARCH
Cyclin E and c-Myc promote cell proliferation in the presence of p16 INK4a and of hypophosphorylated retinoblastoma family proteinsThe EMBO Journal Article (01 Sep 1997)
A novel function of adenovirus E1A is required to overcome growth arrest by the CDK2 inhibitor p27 Kip1The EMBO Journal Article (15 Oct 1998)
See all 51 matches for Research